Inicio - IMIM IMIM

PLAY VIDEO ►

"In 2021 we were able to improve our evaluation in a year in which was particularly strict, we have move up a place in our standing as a research centre within the Catalan research system. It is also worth noting that over the past year we have increased our success rate in both national and international competitive projects, some of which are extremely prestigious"

Joaquín Arribas

DIRECTOR OF HOSPITAL DEL MAR MEDICAL RESEARCH INSTITUTE (IMIM) AND RESEARCH DIRECTOR OF PARC DE SALUT MAR

PLAY VIDEO ►

"MAR Health Park has presented this year's strategic plan that looks towards 2030. Research plays a very prominent role, as it has done up to now, but we would like to further emphasise the important part played by research, in which the capacity to transfer knowledge, the capacity to generate this know-how, the capacity to innovate and, above all, the capacity to create and retain talent, can grow. It is an indispensable tool for our organisation."

Olga Pané

MANAGER OF HOSPITAL DEL MAR-PARC DE SALUT MAR

Overview of the year

Research Programs

Relevant Projects

Clinical Trials

Publications

Core Facilities

Funding

Personnel

Communication and Public Engagement

Research Programs

Biomedical Informatics

PROGRAM DIRECTOR

Mar Albà

GROUPS

Computational methods to understand and predict biological phenomena related to human diseases, their diagnosis and pharmacological treatment.

+ INFORMATION ►

Cancer

PROGRAM DIRECTOR

Joan Albanell

GROUPS

Our research aims to deliver innovative findings for precision medicine and immunotherapy in cancer patients.

+ INFORMATION ►

Epidemiology and Public Health

PROGRAM DIRECTOR

Jordi Alonso

GROUPS

We translate our research into public health and clinical practice, and we innovate in the preventive and health care assessment fields.

+ INFORMATION ►

Neurosciences

PROGRAM DIRECTOR

Rafael de la Torre

GROUPS

We support clinical research that should ultimately give us a better understanding of mental and neurodegenerative diseases.

+ INFORMATION ►

Translational Clinical Research

PROGRAM DIRECTOR

Xavier Nogués

GROUPS

We study the pathophysiology of a variety of disorders involving inflammatory processes in order to develop novel therapeutic approaches.

+ INFORMATION ►

▲
OVERVIEW OF THE YEAR

Relevant Projects

"I believe that IMIM continues to occupy a very important and unique niche in the national and international scientific ecosystem, and I feel that the foundations have been laid so that this effort, this scientific productivity, and this transfer of its activities to society can be maintained, consolidated and even increased over the course of 2022."

Xosé R. Bustelo

CSIC Research Professor, Salamanca Cancer Research Center (CSIC-University of Salamanca). Vice-director, Salamanca Cancer Research Center. Coordinator, Mechanisms of Tumor Progression Program of the Spanish Network for Biomedical Research in Cancer (CIBERONC)

Funding from Research Projects by Program

EPIDEMIOLOGY AND PUBLIC HEALTH
3.584.980,23€

TRANSLATIONAL CLINICAL RESEARCH
4.850.293,22€

CANCER
8.254.860,55€

NEUROSCIENCES
12.643.935,46€

BIOMEDICAL INFORMATICS
4.907.942,89€

OTHER (HOSPITAL AND MANAGEMENT)
285.215,00€

Outstanding Projects

GO-DS21 Study
(H2020 EU funded project)

Rafael de la Torre

DIRECTOR OF THE NEUROSCIENCES PROGRAMME AT IMIM

Down's syndrome, also known as trisomy-21, is a genetic disorder in which a person has three copies of chromosome 21 instead of the usual two. It is associated with a high risk of both severe obesity and intellectual disorders. According to the hypothesis that the locus may be on chromosome 21, the EU-funded GO-DS21 project is investigating the genetic mechanisms of these comorbidities. A cohort of 100 subjects with Down's syndrome is being evaluated at the IMIM as part of this project. More info: https://go-ds21.eu/

PSYBIAS ERA-Net NEURON

Jana Selent

HEAD OF GPCR DRUG DISCOVERY GROUP AT IMIM

PSYBIAS ERA-Net NEURON: A novel paradigm for effective and safer treatment of schizophrenia: biased (ant) agonists with a characterized polypharmacological profile. The treatment of schizophrenia remains a complex challenge: Up to 30% of patients are resistant and up to 30% more respond only partially to antipsychotic treatment. Most of the patients that receive treatment suffer diverse side effects. The aim of this project is to develop a framework for improved medication. The project uses a multidisciplinary approach grounded in novel concepts such as signalling bias and polypharmacology applied to antipsychotic drug targets. Specifically, we are focusing on two main objectives: firstly, the implication of specific signalling pathways in distinct schizophrenia symptoms; secondly, we will translate our insights into lead- and drug-like candidates with an improved therapeutic profile. More info: https://www.neuron-eranet.eu/wp-content/uploads/_media/PSYBIAS_summary.pdf

Primary and secondary failure to respond to anti-TNF therapy in ulcerative colitis: the role of microbiota-specific and drug-specific mucosal antibodies

IP: Giuliana Magri
Co IP: Lucía Márquez

Clinical response to anti-tumour necrosis factor (TNF) therapy in ulcerative colitis (UC) is limited to a subgroup of patients due to lack of primary response or loss of secondary response. In addition to determining infratherapeutic serum drug levels, several biomarkers of non-response have been proposed, but none of these are used in clinical practice. For this reason, understanding the mechanisms of molecular anti-TNF resistance is a priority goal.

Mendelian Randomization to Assess Causal Genetic Pathways of Severe COVID-19

Jaume Marrugat

HEAD OF THE REGICOR GROUP AT IMIM

The aim of this project is to use genetic information to determine the mechanisms that lead to the development of severe forms of COVID-19 (hospitalisation or persistent symptoms). The outcomes include identifying causal pathways that may constitute a therapeutic target and subsequently lead to the development of new drugs for treating SARS-CoV-2 and preventing "long COVID" in >3,500 patients.

INtegrative GENomic, digital Imaging and clinical information towars Precision Oncology Optimization INGENIO.

Joan Albanell

DIRECTOR OF THE CANCER RESEARCH PROGRAMME AT IMIM AND HEAD OF THE ONCOLOGY DEPARTMENT AT HOSPITAL DEL MAR

Cancer is a major global public health problem and the leading cause of cardiovascular disease mortality in developed countries. In recent decades, treatments tailored to specific genetic aberrations in cancer cells and novel immunotherapy approaches have paved the way for precision medicine and personalised cancer care. The structure of this project boosts precision oncology through harmonized predictive biomarker implementation, digital imaging, and pathology plus the exploitation of well-annotated cohorts (clinically and genomically) using artificial intelligence with an interdisciplinary approach. The goal is to effectively translate the outcomes to the real-life clinical setting.

▲
OVERVIEW OF THE YEAR

Clinical Trials

"We can be very satisfied with the results for 2021.The increase in trials has been the most important in recent years."

Miguel Pera

Chief Medical Officer and Chair of Surgery en Hospital del Mar- Parc de Salut MAR

Clinical Trials Signed in 2021

EPIDEMIOLOGY AND PUBLIC HEALTH

TRANSLATIONAL CLINICAL RESEARCH

CANCER

NEUROSCIENCES

OTHER (HOSPITAL AND MANAGEMENT)

TOTAL

155

Clinical trials 2017-2021

Relevant Clinical Trials

Multicentre study to evaluate the safety and efficacy of psilocybin, in patients with treatment-refractory depression after completion of the COMP 001 and COMP 003 (P-TRD LTFU) trials. COMPASS Study.

Víctor Pérez. Head of the Mental Health group at the IMIM and Director of the Institute of Neuropsychiatry and Addictions at Hospital del Mar (INAD).

Psilocybin is a psychoactive hallucinogenic alkaloid from mushrooms. The effectiveness of psilocybin therapy is being investigated in treatment-resistant depression. Psilocybin therapy combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. A synthesized formulation of psilocybin COMP360 developed by COMPASS Pathways is being investigated.

MyPeBS: International Randomized Study Comparing Personalized, Risk-Stratified Screening to Standard Breast Cancer Screening in Women Aged 40-70.

Marta Román. Epidemiology and Evaluation group at the IMIM and Hospital del Mar.

MyPeBS (My Personal Breast Screening) is a multi-centre, international, randomised clinical study that aims to assess the effectiveness and feasibility of personalised breast cancer screening, based on each individual woman's personal risk of developing breast cancer . This study will compare current standard breast screening with a personalised strategy, which screens women at higher risk of breast cancer more often, and women at a lower risk of breast cancer less often. The study will recruit 85,000 women aged 40 to 70 in 6 countries: Belgium, France, Israel, Italy, the United Kingdom and Spain.
More info

Phase I, multicentre, open-label study to evaluate the safety, tolerability and pharmacokinetics of escalating doses of RO7082859, administered after giving a single fixed dose of obinutuzumab (GAZYVA®/GAZYVARO™), to patients with relapsed/refractory B-lymphocyte non-Hodgkin lymphoma.

Antonio Salar. Applied clinical research in the Haematological Malignancies group at the IMIM and head of the Haematology Department at Hospital del Mar.

Patients suffering refractory/relapsed B-cell non-Hodgkin lymphoma have a poor outcome with standard therapies. This phase I clinical trial is based on the administration of a new bispecific monoclonal antibody CD20/CD3 (glofitamab) as a single agent as well as in combination with obinutuzumab. By simultaneously binding to CD20+ tumour cells and CD3+ T-cells, it induces tumour cell lysis, T-cell activation, proliferation and cytokine release to eliminate the B-cells of aggressive lymphoma tumours.

Randomized clinical trial to assess the feasibility and utility of a multimodal prehabilitation program intervention for kidney transplant candidates on the waiting list.

Maria José Pérez Sáez. Kidney Disease group at the IMIM and chief of the renal transplant section.

Frailty is very frequent among Chronic Kidney Disease patients who are on the waiting list for deceased donor for kidney transplants, and the outcome of the transplant is worse in frail recipients. Frailty and low fitness powerfully predict mortality, kidney graft survival, and healthcare use after a kidney transplant. Intervention is essential for improving the quality of life of frail Chronic Kidney Disease patients, regardless of their age. A pre-transplant clinical framework for multimodal prehabilitation interventions including physical therapy, nutritional measures and psychological support scheduled prior to the transplant may improve patient retention and compliance, somewhat mitigating the effects of frailty and low fitness levels after a kidney transplant, and improving the main outcomes in frail Chronic Kidney Disease patients.

▲
OVERVIEW OF THE YEAR

Publications

"In 2021 we have published more and we have published better than in the previous year."

Beatriz Bellosillo

Applied clinical research in hematological malignancies group at the IMIM and head of CAP SECCIO BIOLOGIA MOLECULAR

Publications by Program

EPIDEMIOLOGY AND PUBLIC HEALTH

TRANSLATIONAL CLINICAL RESEARCH

CANCER

NEUROSCIENCES

BIOMEDICAL INFORMATICS

TOTAL INDEXED PUBLICATIONS

2020

TOTAL PUBLICATIONS

(indexed and none indexed)

1130

2021

TOTAL PUBLICATIONS

(indexed and none indexed)

1494

2020

512

1st quartile

229

1st decile

Total publicacions

2021

688

1st quartile

284

1st decile

Total publicacions

Relevant Publications

Ehrmann S, Li J, Ibarra-Estrada M, Perez Y, Pavlov I, McNicholas B, Roca O, Mirza S, Vines D, Garcia-Salcido R, Aguirre-Avalos G, Trump MW, Nay MA, Dellamonica J, Nseir S, Mogri I, Cosgrave D, Jayaraman D, Masclans JR, Laffey JG, Tavernier E; Awake Prone Positioning Meta-Trial Group.

Awake prone positioning for COVID-19 acute hypoxaemic respiratory failure: a randomised, controlled, multinational, open-label meta-trial. Lancet Respir Med. 2021 Dec;9(12):1387-1395. Doi: 10.1016/S2213-2600(21)00356-8.

Mariona Torrens-Fontanals, Alejandro Peralta-García, Carmine Talarico, Ramon Guixa-Gonzalez, Toni Giorgino, and Jana Selent

SCoV2-MD: a database for the dynamics of the SARS-CoV-2 proteome and variant impact predictions. Nucleic Acids Research 50(D1):D858-D866.

Farràs M*, Almanza E, Hernáez A, Agustí N, Julve J, Fitó M, Castañer O*.

Beneficial effects of olive oil and Mediterranean diet on cancer physio-pathology and incidence. Semin Cancer Biol 2021; 73: 178-195. DOI 10.1016/j.semcancer.2020.11.011

Arenas EJ, Martínez-Sabadell A, Rius Ruiz I, Román M, Escorihuela M, Luque A, Fajardo CA, Gros A, Klein C, Arribas J*.

Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation Nat Commun 2021; 12(1): 1237. Doi: 10.1038/s41467-021-21445-4.

Sanchez-Larsen A, Principe A, Ley M, Navarro-Cuartero J, Rocamora R.

Characterization of the Insular Role in Cardiac Function through Intracranial Electrical Stimulation of the Human Insula. Ann Neurol. 2021 Jun;89(6):1172-1180. Doi: 10.1002/ana.26074.

▲
OVERVIEW OF THE YEAR

Core Facilities

"We are long-term users and our experience has been very positive."

Montse Fitó

Head of Cardiovascular risk and nutrition group at the IMIM

MARBiobanc

MARGenomics

304

projects

1.875

transferred samples

3.104

processed samples

2.334

analyzed samples

active funded projects

Publications

IMIM Internal Facilities

Histology

Microscopy

Radioactive Facilities

Cell-Culture Facilities

Cryopreservation Unit

Bioluminescence/Fluorescence Facility (IVIS)

Other IMIM resources

Clinical Research Unit (IMIM)

https://www.imim.es/ofertadeserveis/assajos_clinics/en_index.html

Drug Research Ethical Committee (CEIm-PSMar)

https://www.imim.es/comitesetics/ceic/en_index.html

Molecular Cytogenetics (IMIM)

https://www.imim.es/sct/citogen_tica/en_index.html

Quality-of-Life Questionnaires (IMIM)

https://www.bibliopro.org/

Other PRBB Shared Facilities

Bioinformatics (CRG)

https://biocore.crg.eu/wiki/Main_Page

National Center for Genomic Analysis (CNAG-CRG)

https://www.cnag.crg.eu/

Flow Cytometry (CRG-UPF)

https://www.crg.eu/en/core/programmes-groups/crgupf-facs-unit

PRBB Animal Experimentation Ethics Committee (CEEA- PRBB)

https://www.prbb.org/ciencia.php#Animalario

Biosafety Committee (CBS-PRBB)

https://www.prbb.org/ciencia.php#Servicios

Biomolecular Screening and Protein Technologies (CRG)

https://www.crg.eu/en/programmes-groups/biomolecular-screening-protein-technologies-unit

European Genome-Phenom Archives (CRG)

https://ega-archive.org/

Genomics (CRG)

https://www.crg.eu/en/programmes-groups/genomics-unit

Genomics UPF

https://www.upf.edu/web/sct-genomics/home

Tissue Engineering (CRG)

https://www.crg.eu/en/programmes-groups/tissue-engineering-unit-0

Mesoscopic Microscopy (EMBL)

https://www.embl.org/groups/mesoscopic-imaging-facility/

Advanced Optical Microscopy (CRG-UPF)

https://www.crg.eu/en/programmes-groups/advanced-light-microscopy-unit

Synthetic Peptides (UPF)

https://www.upf.edu/web/sct-peptide-synthesis

Proteomics (CRG-UPF)

https://www.crg.eu/en/programmes-groups/crgupf-proteomics-unit

Animal Facility

https://www.prbb.org/ciencia.php#Servicios

▲
OVERVIEW OF THE YEAR

Funding

"In 2021, the IMIM improved its fundraising partly due to the incorporation of young talent but also due to the emergence in our sector of the Next Generation funds."

Marta López

Head of Competitive Funding at the IMIM

Sources of Funding

COMPETITIVE

2020

11.128.196,95€

COMPETITIVE

2021

10.430.675,86€

European Union

Other International Grants

National Grants

Public bodies of Generalitat

NON COMPETITIVE

2020

8.484.938,92€

NON COMPETITIVE

2021

9.498.720,33€

Clinical trials

Research contracts

Donations

Technology transfer

Analytics and Quality Controls

Others

TRUSTEES CONTRIBUTION
(Generalitat de Catalunya)

2020

3.133.333,84€

2021

3.402.097,46€

TOTAL

23,331,493.65€

COMPETITIVE
10.430.675,86€

NON COMPETITIVE
9.498.720,33€

TRUSTEES CONTRIBUTION (Generalitat de Catalunya)
3.402.097,46€

Outstanding Competitive Grants

Pharmacogenomics of anti-VEGF in patients with Age-Related Macular Degeneration

PRINCIPAL INVESTIGATOR

Ana Aldea

BUDGET

379.525€

PERIOD

01/01/2022-31/12/2025

PROJECT

ISCIIII Independent Clinical Research Projects

Recreation of the embryonic niche for the production of haematopoietic stem cells and their derivatives in human gastruloids

PRINCIPAL INVESTIGATOR

Anna Bigas

BUDGET

374.602€

PERIOD

01/12/2021- 30/11/2024

PROJECT

Spanish State Research Agency Projects in Strategic Areas

▲
OVERVIEW OF THE YEAR

Personnel

"Attracting and nurturing talent is one of the IMIM’s main areas of interest."

Vanesa Nogales

Deputy Director, IMIM

Personnel

TRANSLATIONAL CLINICAL RESEARCH
201,00

CANCER
165,00

NEUROSCIENCES
153,00

EPIDEMIOLOGY AND PUBLIC HEALTH
120,00

MANAGEMENT
43,00

BIOMEDICAL INFORMATICS
28,00

HOSPITAL
15,00

CORE FACILITIES
12,00

Researchers Type by Gender

WOMEN
(260)

MEN
(191)

TOTAL
(451)

Researcher

Collaborating researcher

Postdoctoral researcher

Predoctoral researcher

Researchers Profile by Gender

WOMEN
(260)

MEN
(191)

TOTAL
(451)

R4 Leading Researcher

R3 Established Researcher

R2 Recognized Researcher

R1 First Stage Researcher

▲
OVERVIEW OF THE YEAR

Communication and Public Engagement

"It is essential that the gap between society and science becomes smaller and smaller, and that society understands that science is very important."

Arnau Busquets

Head of the Cell-type mechanisms in normal and pathological behavior at the IMIM

Media

2020

PRESS RELEASES

NEW APPEARANCES

1860

Web
1160

Press
593

Radio
75

TV
32

2021

PRESS RELEASES

NEW APPEARANCES

1828

Web
1471

Press
233

Radio
89

TV
35

Press Releases With the Greatest Impact

New diagnostic marker for pancreatic cancer identified

IMPACTS

307

Navarro Medrano, Pilar, Martinez, Neus, Visa, Laura. Barranco Luis

El Periódico

Not all “good” cholesterol is healthy

IMPACTS

Roberto Elosua

La Vanguardia

Radical increase in the effectiveness of breast cancer immunotherapy

IMPACTS

Toni Celià-Terrassa , Iván Pérez-Núñez, and Joan Albanell

La Vanguàrdia

The benefits of the Mediterranean diet pass on to the families of patients who follow it

IMPACTS

Olga Castañer and Albert Goday

TVE

Mixing energy drinks with alcohol can increase the risk of a traffic accident

IMPACTS

Clara Pérez and Rafael de la Torre

TV3

A higher heart rate is associated with a greater risk of death

IMPACTS

Roberto Elosua and Albert Clarà

TV3

Website and Social Media

WEB VISITS

96142

FOLLOWERS

9259

NEW FOLLOWERS

762

TOP TWEET (IMPRESSIONS)

8513

FOLLOWERS

7870

TOP PUBLICATION (IMPRESSIONS)

Outreach

CAMPAIGNS

International Day of Women and Girls in Science (She Inspired me) - 11 February

Objective: Campaign to raise the visibility of women in science. At the IMIM we are once again celebrating the International Day of Women and Girls in Science and supporting the #SheInspiredMe campaign.

TOTAL AUDIOVISUAL CONTENT:
Creation of 6 videos with 1633 views

SOCIAL MEDIA:
32 tweets with 37,937 impressions
6 posts with 1534 likes and 21,817 impressions

MORE INFO

International Clinical Trials Day - 20 May

Objectives: Campaign to improve public awareness of clinical trials and to recruit volunteers to participate in clinical trials.

TOTAL AUDIOVISUAL CONTENT:
12 videos with researchers recorded.

SOCIAL MEDIA:
2 posts and 3 stories: 16,709 impressions and 312 interactions.
LIVE: 187 people connected live and 2,225 views.
11 tweets with 21,142 impressions
Graphic pieces: Promotional banners

MORE INFO

World Cancer Research Day - 24 September

Objectives: Campaign to raise awareness of the need for cancer research and to highlight the research work carried out by IMIM researchers.

TOTAL AUDIOVISUAL CONTENT:
2 informational videos about IMIM's cancer research recorded

SOCIAL MEDIA:
8 tweets with 4,790 impressions.
1 post with 6,119 impressions.

ACTIVITIES FOR THE GENERAL PUBLIC

Participation in the project "La Mare de la Ciència" - July 28

Objective: To publicise the research through the eyes of the researchers involved by recording the podcast “Deciphering metastasis”. In this episode Dr. Antoni Celià-Terrassa, researcher in the IMIM’s cancer programme, explains the characteristics of metastatic cells and the treatments they are studying to combat these.

TOTAL PLATFORMS WHERE IT HAS BEEN PUBLISHED:
Spotify, Google Podcast, Apple Podcast, Ivoox and Spreaker where it has been played 298 times

MORE INFO

Open PRBB -October 18-23

Objective: To introduce science to the general public in order to promote scientific culture and facilitate knowledge through participation in the PRBB's Open Day, which this year has had a hybrid format.

TOTAL • Video "What is a biobank" with: 433 views on YouTube, 163 on Instagram and 178 on Facebook
• Virtual lab live tours of the IMIM's cancer and stem cell laboratory: 211 views on YouTube
• Participation in the round table on the gender perspective in biomedical research: 190 views and 60 attendees

MORE INFO

Participation in the 2021 Science Festival - June 13

Objective: To disseminate information and prevent infections.

Activity: Workshop "Do you know how to apply good hand hygiene?" held by technicians from Hospital del Mar who showed how to perform good hand hygiene using hydroalcoholic gel.

TOTAL 80 ATTENDEES

MORE INFO

ACTIVITIES FOR STUDENTS

Pilot test "Science Journalist- May 27

Objective: To carry out a pilot test to assess the suitability of setting up the "Science Journalist" activity organised by the PRBB with the participation of all the centres, aimed at pupils aged between 10 and 12 years of age.

Activity: The children prepare COVID-19-related questions at school and ask them live to Dr. Imma López Montesinos, researcher in the Infectious Pathology and Antimicrobials research group at the IMIM and a doctor in the Infectious Diseases Service at Hospital del Mar.

TOTAL Participants: 40 STUDENTS

Fundraising

Campaigns organised by the IMIM with the support of the Amics del Hospital del Mar Foundation for breast cancer research. Creating the challenge, Immunotherapy and you, hope against cancer

2021

Social ads on Facebook and Instagram campaign

2021

Organisation of charity sporting events

Nordic Walking 2021 - 7th Marina WalkTrail

2021

Organisation of a meeting on "Sexuality and breast cancer. Rediscovering desire"

2021

Alliance with the adult film producer, Erika Lust, to develop a P2P campaign to support research into immunotherapy and breast cancer.

2021

Agreement with the paddle surf company, Molokai to develop an activity to support research into immunotherapy and breast cancer. VII Christmas charity paddle

We also support campaigns for research into COVID-19 like the "Roses that heal campaign", RepteESADE Green 4 -COVID 19 by MBA students (Beach clean-up and Jailbreak escape room), and we collaborate with the publisher Norma Comics.

▲
OVERVIEW OF THE YEAR

Highlights

4.02.2022

											The Science and Innovation Minister gets a first-hand look at cancer research at the IMIM-Hospital del Mar										

27.01.2022

New diagnostic marker for pancreatic cancer identified

27.12.2021

											Aelis Farma announces good results from its first administration in humans for AEF0217, its first drug candidate for the treatment of cognitive disorders in Down syndrome										

14.12.2021

											New online tool for predicting the impact of SARS-CoV-2 mutations on its protein components										

23.11.2021

											Having suffered a stroke increases the risk of dying after surviving COVID-19 by up to three times.										

10.11.2021

											The IMIM and Hospital del Mar receive more than €1.1M from the new ISCIII RICORS networks										

19.10.2021

											Utility of a new therapeutic target in the immunotherapy treatment of one of the most aggressive breast cancers is demonstrated										

18.10.2021

											The Hospital del Mar Medical Research Institute obtains almost 800,000 euros in new grants from the State Research Agency.										

1.10.2021

Iron supplements improve physical fitness and quality of life in COPD patients

16.09.2021

The Mediterranean diet helps improve cognitive function and memory

12.08.2021

											Way to avoid treatment resistance for one of the most aggressive breast cancers identified										

29.07.2021

Mechanism that triggers brain neurone response revealed

13.07.2021

A new approach to metastatic melanoma discovered

8.07.2021

											Record funding for the Hospital del Mar Medical Research Institute from the Healthcare Research Projects at the Carlos III Institute of Health.										

22.06.2021

More than 6% of Europeans suffer from depression

16.06.2021

Launch of European research into radiotherapy for cardiac arrhythmias

19.05.2021

											Liquid biopsy can predict relapse in patients with locally advanced rectal cancer										

8.04.2021

											Model developed for predicting long-term breast cancer risk in women participating in screening programmes										

12.03.2021

											Recognition of Dr. Marta Torrens for her contribution to research on addictions in Europe										

26.02.2021

Not all “good” cholesterol is healthy

16.02.2021

											The effects of treatment with antidepressant drugs evaluated through the analysis of patients’ tweets										

About us

Inaugurated in 1948 by Dr. Alexander Fleming, the Hospital del Mar Medical Research Institute (IMIM) is a center of excellence for biomedical and health research.

IMIM is part of the Parc de Salut Mar consortium, and it is made up of more than 700 professionals, with a mixed composition of IMIM researchers and clinical researchers from Hospital del Mar and other academic researchers from UPF and UAB.

IMIM has the recognition of CERCA as a Catalan Research Institute of Excellence, ISCIII as Health Research Institute and European Commission with the HR Excellence in Research Award.

Its proximity to Hospital del Mar and the Campus Universitari Mar, and its location in a solid scientific ecosystem like PRBB, means that IMIM is in a privileged biomedical enclave in Barcelona.

IMIM’s translational research is carried out through five well-structured research programs: epidemiology and public health, neuroscience, cancer, biomedical informatics, and clinical translational research programs.

Our Mission

To conduct excellent translational research to be an international reference in biomedical research.

Future Challenges

Excellence in scientific activity through internationalization and attracting talent

Sustainable growth through cost-effective investment of resources and promotion of development

Seamless linkage to society through highly translational research aligned with PSMAR’s strengths

Board

Chair

Josep Maria Argimon Pallàs

Minister of Health

FIRST VICE-PRESIDENT

Gemma Geis Carreras

Minister of Research and Universities

SECOND VICE-PRESIDENT

Davide Malmusi

Vice-president of the Governing Council of Barcelona Mar Health Park Consortium

MEMBERS

Javier Lafuente Sancho

Rector of Universitat Autònoma de Barcelona

Oriol Amat Salas

Rector of Universitat Pompeu Fabra

Joan Gómez Pallarès

General Director for Research Ministry of Business and Knowledge

Aina Plaza Tesías

Appointed by the Ministry of Health

Olga Pané Mena, Miguel Pera, Josep Aumatell, Narcís Pérez de Puig (acting Secretary)

Appointed by the Barcelona Mar Health Park Consortium

Armand Sánchez Bonastre

Appointed by Universitat Autònoma de Barcelona

José García Montalvo

Appointed by Universitat Pompeu Fabra

Executive Committee

Chair

Aina Plaza Tesías

Members

Joan Gómez Pallarès

General Research Director Ministry of Business and Knowlegde

Armand Sánchez Bonastre

Appointed by the Universitat Autònoma de Barcelona

José García Montalvo

Appointed by the Universitat Pompeu Fabra

Olga Pané Mena, Narcís Pérez de Puig (acting Secretary)

Appointed by the Barcelona Mar Health Park Consortium

Scientific Advisory Board (SAB)

President

Xosé R Bustelo PhD

Deputy Director of the Cancer Research Center (CIC), University of Salamanca-CSIC (Salamanca, Spain)

Members

Gervaise Loirand

DR1 Inserm Team leader III "Signaling and vascular and pulmonary pathophysiology", Deputy director of the UMR Inserm 1087 / Cnrs 6291 L'Institut du Thorax. Université de Nantes. France

Gitte Knudsen

Chair, Professor, MD, DMSc. Dept. Neurology and Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark

Caroline Sabin

Professor of Medical Statistics and Epidemiology. Infection & Population Health, Institute for Global Health. Faculty of Pop Health Sciences. UCL Principal Supervisor, UCL Subsidiary Supervisor. University College London, UK.

Luca Gianni

Milan, Italy. Director, Medical Oncology, Head of the New Drug Development Laboratory of Clinical Pharmacology. Ospedale San Raffaele. President, Michelangelo Foundation.

Alvis Brazma

Functional Genomics Senior Team Leader and Senior Scientist. EMBL-EBI, UK.

Research Programmes

Biomedical Informatics

https://www.imim.es/programesrecerca/informaticabiomedica/en_index.html

Cancer

https://www.imim.es/programesrecerca/cancer/en_index.html

Epidemiology and Public Health

https://www.imim.es/programesrecerca/epidemiologia/en_index.html

Neuroscience

https://www.imim.es/programesrecerca/neuropsicofarmarcologia/en_index.html

Translational Clinical Research